HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM.

Abstract
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches-immune detection coupled with magnetic beads and fluorescence-activated cell sorting-were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity.
AuthorsGuillaume Belthier, Zeinab Homayed, Fanny Grillet, Christophe Duperray, Julie Vendrell, Ilona Krol, Sophie Bravo, Jean-Christophe Boyer, Olivia Villeronce, Jihane Vitre-Boubaker, Diana Heaug-Wane, Françoise Macari-Fine, Jai Smith, Matthieu Merlot, Gérald Lossaint, Thibault Mazard, Fabienne Portales, Jérôme Solassol, Marc Ychou, Nicola Aceto, Emilie Mamessier, François Bertucci, Jean Marc Pascussi, Emmanuelle Samalin, Frédéric Hollande, Julie Pannequin
JournalCancers (Cancers (Basel)) Vol. 13 Issue 19 (Oct 02 2021) ISSN: 2072-6694 [Print] Switzerland
PMID34638450 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: